Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13:48 | Evaxion Out-licenses Vaccine Candidate EVX-B3 To Merck & Co. | 198 | AFX News | KENILWORTH (NJ) (dpa-AFX) - TechBio company Evaxion A/S (EVAX) announced Thursday it has out-licensed its vaccine candidate EVX-B3 to Merck & Co., Inc. or MSD (MRK), as per the option and license... ► Artikel lesen | |
13:15 | Evaxion A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
13:10 | Evaxion out-licenses vaccine candidate EVX-B3 to MSD | 236 | GlobeNewswire (Europe) | MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion's cash runway to first half of 2027 MSD will assume full responsibility for the further... ► Artikel lesen | |
13:06 | MSD exercises option on Evaxion's vaccine candidate for $7.5 million | 6 | Investing.com | ||
27.08. | Evaxion A/S - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
EVAXION Aktie jetzt für 0€ handeln | |||||
27.08. | Evaxion to present at several conferences during the second half of 2025 | 339 | GlobeNewswire (Europe) | Evaxion will provide scientific and company updates at numerous conferences in both the US, Europe and Asia during the coming months
COPENHAGEN, Denmark, August 27, 2025 - Evaxion A/S (NASDAQ: EVAX)... ► Artikel lesen | |
14.08. | Evaxion Biotech ADS GAAP EPS of -$0.02 | 2 | Seeking Alpha | ||
14.08. | Evaxion announces business update and second quarter 2025 financial results | 416 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, August 14, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, provides business update and... ► Artikel lesen | |
13.08. | Insights Ahead: Evaxion Biotech's Quarterly Earnings | 1 | Benzinga.com | ||
11.08. | Evaxion A/S - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
11.08. | Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 | 268 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, August 11, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will provide a business update... ► Artikel lesen | |
25.07. | Evaxion A/S - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
25.07. | Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 | 424 | GlobeNewswire (Europe) | COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, will be presenting two-year clinical... ► Artikel lesen | |
11.07. | Evaxion finalizes €3.5 million debt-to-equity deal with EIB | 3 | Investing.com | ||
11.07. | Evaxion schließt Debt-to-Equity-Vereinbarung mit EIB über 3,5 Millionen Euro ab | 5 | Investing.com Deutsch | ||
11.07. | Evaxion A/S - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
11.07. | Evaxion finalizes agreement with EIB to convert debt into equity | 380 | GlobeNewswire (Europe) | Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 million out of Evaxion's €7 million loan with EIB, to be used for EIB to purchase €3.5 million worth... ► Artikel lesen | |
02.07. | Evaxion A/S - 6-K, Report of foreign issuer | - | SEC Filings | ||
01.07. | Evaxion Biotech: Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology platform and portfolio | 401 | GlobeNewswire (Europe) | Chief Executive Officer (CEO) Christian Kanstrup steps down Chief Scientific Officer Birgitte Rønø appointed interim CEO and search for new CEO has commencedThomas Schmidt appointed permanent Chief... ► Artikel lesen | |
25.06. | Evaxion entwickelt neuen Impfstoff gegen Gruppe-A-Streptokokken | 6 | Investing.com Deutsch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 84,25 | -0,94 % | PAUKENSCHLÄGE bei Megatrend-Aktien: Rheinmetall, BioNTech, First Hydrogen | Rheinmetall gibt Vollgas: zu Land, zu Wasser, in der Luft und im Weltraum. Jüngster Paukenschlag ist die angekündigte Übernahme der Marinesparte von Lürssen. Ist das der Rückenwind für die Aktie, um... ► Artikel lesen | |
EVOTEC | 6,040 | -3,02 % | Adidas schluckt Puma? Evotec mit Insiderkauf! 50 % Kurspotenzial mit KI-Aktie NetraMark! | Adidas und Puma im Fusionsfieber? Ein US-Investor bringt die spektakuläre Idee ins Spiel. Ist es ein Druckmittel gegenüber dem Puma-Management oder tatsächlich eine Option? Was sagen Analysten? Währenddessen... ► Artikel lesen | |
QIAGEN | 37,670 | -1,96 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 50 Euro auf "Buy" belassen. Der Diagnostikspezialist liege mit seinen Innovationen im Bereich... ► Artikel lesen | |
CUREVAC | 4,548 | -0,44 % | Laufende Fusionskontrollverfahren: BioNTech SE, Mainz; Erwerb von bis zu 100% der Anteile an und alleinige Kontrolle über CureVac N.V., Tübingen | Datum der Anmeldung:18.09.2025Aktenzeichen:B3-86/25Unternehmen:BioNTech SE, Mainz; Erwerb von bis zu 100% der Anteile an und alleinige Kontrolle über CureVac N.V., TübingenProduktmärkte:biotechnologische... ► Artikel lesen | |
PAION | 0,020 | -13,04 % | Paion Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
AMGEN | 235,90 | -0,84 % | EMA Backs Amgen Drug For Rare Autoimmune Disorder | ||
NOVAVAX | 7,181 | -2,50 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
STRYKER | 311,40 | -1,49 % | Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures | ||
BIOGEN | 119,65 | +1,96 % | Biogen Inc.: LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia | TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts... ► Artikel lesen | |
CRISPR THERAPEUTICS | 52,00 | -0,95 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
OCUGEN | 1,230 | -11,74 % | Forecasting The Future: 4 Analyst Projections For Ocugen | ||
SCISPARC | 7,750 | +102,35 % | SciSparc stock soars after launching quantum computing initiative | ||
ENLIVEN THERAPEUTICS | 19,200 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
IMMUNEERING | 8,060 | -12,30 % | Morning Market Movers: PepGen, 22nd Century Group, Immuneering, Transocean See Big Swings | OTTAWA (dpa-AFX) - At 7:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |